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Figure. Specimen testing for ciHHV-6
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our institution from 1998-2012, 37 (0.95%) met criteria for
HHV-6-PALE. This cohort had 16 double cord blood, 13 pe-
ripheral blood (PBSCT), and 8 bone marrow HCTs. Median
maximum CSF HHV-6 viral load (VL) was 10,000 copies/ml
(range, 54-450,000). Twenty-six cellular and 11 serum pre-
HCT patient samples were tested for ciHHV-6 (Figure).
CiHHV-6 was detected in 1 of 37 samples (2.7%; 95% CI, 0.07-
14.5%). This patient developed HHV-6-PALE D+12 after PBSCT
with maximum CSF VL of 250,000 copies/ml and died on
D+40 from complications of autopsy-conﬁrmed encephalitis.
Nineteen donor samples (17 cellular, 2 serum) tested nega-
tive for ciHHV-6. Late post-engraftment serum samples were
tested in cases without available donor samples; 4 of 15 had
HHV-6 DNA detected but were indeterminate for ciHHV-6
(Figure).
Conclusions: This is the ﬁrst epidemiologic study of the
prevalence of ciHHV-6 in patients with HHV-6 PALE and
included the largest reported cohort of HHV-6-PALE cases to
date. CiHHV-6 was identiﬁed in one patient, which has never
been described in this setting. Sequencing of pre and post-
HCT viruses, as well as histopathologic testing of brain tissue,
is in process. Although there is no clear evidence of ciHHV-6
enrichment in this cohort, the detection and poor outcome
in the described case underscores the need for a large,
multi-center study to determine the impact of ciHHV-6 on
outcomes.354
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Medical College of Wisconsin, Milwaukee, WINMA doses of FluTBI result in successful donor chimerism
and have the objective of controlling disease through a graft-
versus-tumor effect. Other regimens without irradiation
were developed, mainly for treatment of lymphoma, yet
comparisons of HCT outcomes remain scant. We compared
382 FluTBI recipients to 515 Flu recipients prior to HCT from
2001 to 2011 and reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR). Patients
were 40 years or older with lymphoma and received
matched sibling, HLA matched at 8/8 or 7/8 unrelated donor
(URD) bone marrow (BM) or peripheral blood (PBSC) grafts.
FluTBI cohort had a higher number of patients with Kar-
nofsky performance score (KPS) <90% (32% vs. 22%), more
chronic lymphocytic leukemia (41% vs. 33%), more URD (68%
vs. 51%), more PBSC (94% vs. 85%), less anti-thymocyte
globulin use (11% vs. 15%), less rituximab in the conditioning
(7% vs. 40%), and more mycophenolate mofetil-based graft
vs. host disease prophylaxis (GVHD, 87% vs.15%) compared to
Flu. Impact on hematopoiesis differed according to the
regimen with 24% and 43% of patients never dropping the
absolute neutrophil count <500/mL and platelets <50,000/
mL, respectively, with FluTBI comparing to 2% and 24% with
Flu. Cumulative incidences at 100 days of grades II-IV and III-
IV acute GVHD were 22% and 15% with FluTBI; and 17%
(p¼0.04) and 10% (p¼0.02) for Flu, respectively. Corre-
sponding rates of chronic GVHD at 1 year were 54% and 44%
(p¼0.004). Cumulative incidences at 3 years of transplant
related mortality were 28% and 23% (p¼0.13), and of pro-
gression were 36% and 34% (p¼0.63) for FluTBI and Flu
respectively. Multivariate analysis of TRM, progression,
treatment failure and mortality showed no difference in
outcomes according to the conditioning regimen. Variables
associated with higher mortality were age 50-59y (Hazard
Ratio [HR] 1.31, p¼0.03) and 60y (HR 1.66, p<0.001)
compared to 40-49y; KPS <90% (HR 1.49, p<0.001); and
recipients of 8/8 matched URD (HR 1.28, p¼0.02) and 7/8
matched URD (HR 1.94, p<0.001) compared to sibling donor
HCT. The three-year probabilities of progression free survival
were 40% and 41% (p¼0.81), and overall survival were 50%
and 55% (p¼0.14) after adjusting for factors from the
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S231multivariate analysis. TBI regimens have less impact on blood
counts immediate post-transplant period. Despite higher
rates in acute and chronic GVHD with FluTBI, overall out-
comes after HCT are comparable to non-TBI containing NMA
regimens for lymphoma.355
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Patients with class 3 thalassemia with high-risk features for
adverse events after high-dose chemotherapy with he-
matopoietic stem cell transplantation (HSCT) are difﬁcult to
treat, tending to either suffer serious toxicity or fail to
establish stable graft function. We performed HSCT in 21
such patients age 7 years and hepatomegaly using a novel
approach with pretransplant immunosuppression followed
by a myeloablative reduced-toxicity conditioning regimen
(ﬂudarabine and i.v. busulfan [Flu-IV Bu]) and then HSCT. The
median patient age was 15 years (range, 10 to 20 years).
Before the Flu-IV Bu + antithymocyte globulin conditioning
regimen, all patients received 1 to 2 cycles of pretransplant
immunosuppression with ﬂudarabine and dexamethasone.
Fifteen patients received a related donor graft, and 6 received
an unrelated donor graft. An initial prompt engraftment of
donor cells with full donor chimerismwas observed in all 18
patients, but 2 patients developed secondary mixed chime-
rism that necessitated withdrawal of immunosuppression to
achieve full donor chimerism. Three patients (14%) had acute
grade III-IV graft-versus-host disease, and 5 patients had
limited chronic graft-versus-host disease. The only treat-
ment-related mortality was from infection, and with a me-
dian follow-up of 50 months (range, 4 to 83), the 5-year
overall survival and thalassemia-free survival were 93%. We
conclude that this novel sequential immunoablative pre-
transplantation conditioning program is safe and effective
for patients with high-risk class 3 thalassemia exhibiting
additional comorbidities.356
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Wiskott-Aldrich syndrome (WAS) is an X-linked immuno-
deﬁciency presented with eczema, microthrombocytopenia,
autoimmune disorders, recurrent infections, and subsequent
malignancies. Little is known on late complications following
hematopoietic stem cell transplant (HSCT) in this population.
In a single-institutional retrospective study of 17 WAS pa-
tients who underwent HSCT between January 1992 andDecember 2012, we evaluated autoimmune manifestations,
serious infections, and graft-versus-host disease (GVHD).
Median age at HSCT was 2.17 years (range 0.28-12.38). Nine
(52.9%) and eight patients (47.1%) received bone marrow and
umbilical cord blood, respectively. Fourteen patients (82.3%)
underwent HSCT from alternative donors including unre-
lated cord, mismatch family, and match unrelated donors.
Only 2 match sibling (11.7%) and one match related (5.9%)
were used as donors. Median follow-up time was 7.05 years
(range 1.82-19.99).
Two patients (11.7%) died 1 month and 2.1 years post HSCT
due to CMV interstitial pneumonitis and severe Streptococcus
pneumoniae sepsis, respectively. Overall survival (OS) at 2-
year was 87.4%. HLA mismatch and stem cell source were not
signiﬁcant factors for OS (p¼ 0.325 and 0.886, consecutively).
In multivariate analysis, age at HSCT, HLA mismatch, and
stem cell sources were also not signiﬁcant.
Five patients (29.4%) developed acute GVHD grade II-IV. The
incidence of acute GVHD (grade II-IV) was higher when using
bone marrow as a stem cell source (p¼ 0.029). Eight (47.1%)
and three patients (17.6%) developed limited and extensive
GVHD. The incidence of chronic GVHD did not differ by age at
HSCT, HLA mismatch, and stem cell source.
Mixed donor chimerism was temporarily observed in 4 pa-
tients (23.5%). Immunosuppressant was adjusted without
donor lymphocyte infusion. Donor chimerism was subse-
quently improved.
We observed chronic GVHD-independent autoimmune
thrombocytopenia in 4 patients (23.5%). One of those four
also developed warm and cold agglutinin positive autoim-
mune hemolytic anemia. All episodes of autoimmune
thrombocytopenia occurred in patients who received cord
blood transplantation. Mixed donor chimerismwas observed
in 3 of those 4 patients who had persistent thrombocyto-
penia. Only one patient who developed autoimmune
thrombocytopenia and hemolytic anemia received treatment
of plasmapheresis and rituximab. This patient eventually
required regular intravenous immunoglobulin infusion due
to persistent hypogammaglobulinemia. Thrombocytopenia
was gradually subsided with the improvement of donor
chimerism in all patients. No malignancy occurred post-
HSCT in this retrospective cohort.
We report an excellent result using a majority of unmanip-
ulated unrelated and mismatched family donors in this
study. Cytopenias were observed in conjunction with utili-
zation of cord blood stem cells and mixed donor chimerism.357
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Introduction: Reduced intensity conditioning (RIC) allows
older patients and those with comorbidities to undergo
